Literature DB >> 34596801

Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach.

Arthur Winer1, Efrat Dotan2.   

Abstract

OPINION STATEMENT: Pancreatic cancer is increasing in incidence in the USA. This disease disproportionately affects older adults, and as the percentage of adults > 65 years old increases with the aging of the baby boomers, the prevalence is expected to rise over the coming decade. These patients are often more susceptible to disease-related symptoms and have less ability to withstand both cancer and treatment-related side effects. Therefore, it is imperative that treating physicians thoughtfully consider their recommended treatment approach towards this vulnerable patient population. This review focuses on the current state of research of older adults with pancreatic adenocarcinoma, highlighting deficiencies in the representation of this patient population in clinical trials. It is vital that the treating physicians take a nuanced approach towards therapy of localized and metastatic disease in geriatric patients. A one size fits all treatment algorithm is no longer appropriate in any cancer patient, let alone the elders who are particularly vulnerable to developing treatment-related toxicities. To help guide therapy decisions, it is important to perform a comprehensive geriatric assessment which may uncover unexpected frailty and lead to a change in the recommended treatment approach. In this way, we can support older adults during therapy for this aggressive malignancy and provide optimal care.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Comprehensive geriatric assessment; Geriatric; Older adults; Pancreatic cancer; Treatment approach

Mesh:

Year:  2021        PMID: 34596801     DOI: 10.1007/s11864-021-00892-7

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  57 in total

Review 1.  The 2030 problem: caring for aging baby boomers.

Authors:  James R Knickman; Emily K Snell
Journal:  Health Serv Res       Date:  2002-08       Impact factor: 3.402

2.  Under-representation of older adults in cancer registration trials: known problem, little progress.

Authors:  Kevin S Scher; Arti Hurria
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

3.  Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.

Authors:  Ethan B Ludmir; Walker Mainwaring; Timothy A Lin; Austin B Miller; Amit Jethanandani; Andres F Espinoza; Jacob J Mandel; Steven H Lin; Benjamin D Smith; Grace L Smith; Noam A VanderWalde; Bruce D Minsky; Albert C Koong; Thomas E Stinchcombe; Reshma Jagsi; Daniel R Gomez; Charles R Thomas; C David Fuller
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

4.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

Authors:  L F Hutchins; J M Unger; J J Crowley; C A Coltman; K S Albain
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

Review 5.  Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups.

Authors:  Ambuj Kumar; Heloisa P Soares; Lodovico Balducci; Benjamin Djulbegovic
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

6.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

7.  Cancer in older persons: an international issue in an aging world.

Authors:  Rosemary Yancik; Lynn A G Ries
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

8.  Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?

Authors:  Karen W L Yee; Joseph L Pater; Lam Pho; Benny Zee; Lillian L Siu
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

Authors:  Lilia Talarico; Gang Chen; Richard Pazdur
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

10.  Rising trends in pancreatic cancer incidence and mortality in 2000-2014.

Authors:  Wenrui Wu; Xingkang He; Liya Yang; Qing Wang; Xiaoyuan Bian; Jianzhong Ye; Yating Li; Lanjuan Li
Journal:  Clin Epidemiol       Date:  2018-07-09       Impact factor: 4.790

View more
  1 in total

1.  Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study.

Authors:  Yung-Yeh Su; Nai-Jung Chiang; Chung-Pin Li; Chia-Jui Yen; Shih-Hung Yang; Wen-Chi Chou; Jen-Shi Chen; Tai-Jan Chiu; Yen-Yang Chen; Shih-Chang Chuang; Li-Yuan Bai; Chang-Fang Chiu; Cheng-Ming Peng; De-Chuan Chan; Sz-Chi Chiu; Yi-Hsin Yang; Yan-Shen Shan; Li-Tzong Chen
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.